BITRF (Biotron) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Biotron Debt-to-Asset?

Biotron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Biotron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Biotron's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $0.61 Mil. Biotron's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Biotron Debt-to-Asset Historical Data

The historical data trend for Biotron's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Debt-to-Asset Chart

Biotron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.06

0.01

0.02

Biotron Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.02	-

Competitive Comparison of Biotron's Debt-to-Asset

For the Biotechnology subindustry, Biotron's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotron's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotron's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biotron's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Biotron Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biotron's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.005	+	0)	/	0.327
	=	0.02

Biotron's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.609
	=	0.00

Biotron (OTCPK:BITRF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biotron Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biotron's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BIT:Australia

Address

56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113

Website

https://www.biotron.com.au

Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire • 11-25-2021